Close Menu

NEW YORK – Seattle Genetics said Wednesday that its Phase II HER2CLIMB trial for tucatinib in treating HER2-positive metastatic breast cancer yielded positive data. The results were presented at the 2019 San Antonio Breast Cancer Symposium and the accompanying study was published in the New England Journal of Medicine.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.